MTORC1 inhibitors suppress meningioma growth in mouse models

Clinical Cancer Research

Volumn 19, Issue 5, 2013, Pages 1180-1189

  Pachow, Doreen ^a   Andrae, Nadine ^a   Kliese, Nadine ^a   Angenstein, Frank ^b   Stork, Oliver ^a   Wilisch Neumann, Annette ^a   Kirches, Elmar ^a   Mawrin, Christian ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b LEIBNIZ INSTITUTE FOR NEUROBIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MERLIN; MESSENGER RNA; PROTEIN KINASE B; S6 KINASE; TEMSIROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; DRUG TARGETING; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; MENINGIOMA; MITOSIS INDEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENES, NEUROFIBROMATOSIS 2; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MICE; MICE, NUDE; MULTIPROTEIN COMPLEXES; NEOPLASM GRADING; PROTEIN KINASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84874851862     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1904     Document Type: Article

References (28)

1. Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neurooncol 2010;99: 379-91.
2. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 1999;85: 2046-56.
3. Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep 2009;9: 231-40.
4. Wen P, Quant E, Drappatz J, Beroukhim R, Norden A. Medical therapies for meningiomas. J Neurooncol 2010;99: 365-78.
5. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994;6: 180-4.
6. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer- Rachamimov AO, et al. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 2009;29: 4250-61.
7. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124: 471-84.
8. James MF, Stivison E, Beauchamp R, Han S, Li H, Wallace MR, et al. Regulation of mTOR complex 2 signaling in neurofibromatosis 2- deficient target cell types. Mol Cancer Res 2012;10: 649-59.
9. Johnson M, Okedli E, Woodard A, Toms S, Allen G. Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells. J Neurosurg 2002;97: 668-75.
10. Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C, et al. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res 2005;11: 4074-82.
11. Johnson MD, O'Connell M, Vito F, Bakos RS. Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas. J Neurooncol 2009;92: 129-36.
12. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use ofmTORinhibitors in cancer therapy. J Hematol Oncol 2009;2: 45.
13. WuL, BirleDC,Tannock IF. Effectsof themammaliantarget of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005;65: 2825-31.
14. Frost P, Moatamed F, Hoang B, Shi Y, Gera J, Yan H, et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004;104: 4181-7.
15. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun 2005;331: 295-302.
16. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4: 335-48.
17. Haase D, Schmidl S, Ewald C, Kalff R, Huebner C, Firsching R, et al. Fatty acid synthase as a novel target for meningioma therapy. Neuro Oncol 2010;12: 844-54.
18. Puttmann S, Senner V, Braune S, Hillmann B, Exeler R, Rickert CH, et al. Establishment of a benign meningioma cell line by hTERTmediated immortalization. Lab Invest 2005;85: 1163-71.
19. Striedinger K, Vandenberg SR, Baia GS, McDermott MW, Gutmann DH, Lal A. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia 2008;10: 1204-12.
20. Andrae N, Kirches E, Hartig R, Haase D, Keilhoff G, Kalinski T, et al. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells. Eur J Cancer 2012;48: 1831-41.
21. Petermann A, Haase D, Wetzel A, Balavenkatraman KK, Tenev T, Guhrs KH, et al. Loss of the protein-tyrosine phosphatase DEP-1/PTPRJ drives meningioma cell motility. Brain Pathol 2011;21: 405-18.
22. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66: 1500-8.
23. Johnson M, Toms S. Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy? J Neuropathol Exp Neurol 2005;64: 1029-36.
24. Johnson MD, Okedli E, Woodard A, Toms SA, Allen GS. Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells. J Neurosurg 2002;97: 668-75.
25. Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, et al. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer 2005;114: 249-56.
26. Cai DX, James CD, Scheithauer BW, Couch FJ, Perry A. PS6K amplification characterizes a small subset of anaplastic meningiomas. Am J Clin Pathol 2001;115: 213-8.
27. Surace E, Lusis E, Haipek C, Gutmann D. Functional significance of S6K overexpression in meningioma progression. Ann Neurol 2004;56: 295-8.
28. Campen CJ, Porter BE. Subependymal giant cell astrocytoma (SEGA) treatment update. Curr Treat Options Neurol 2011;13: 380-5.